B-type natriuretic peptide: A review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians

Journal of the American Board of Family Practice

Volumn 16, Issue 4, 2003, Pages 327-333

  Cardarelli, Roberto ^a,b   Lumicao Jr , Tomas G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; NERVE PROTEIN; PEPTIDE FRAGMENT;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DEATH; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG MONITORING; EVIDENCE BASED MEDICINE; HEART LEFT VENTRICLE FAILURE; HUMAN; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; PATIENT MONITORING; PHYSICIAN; PRIMARY MEDICAL CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BIOASSAY; BLOOD; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; REPRODUCIBILITY;

BIOLOGICAL MARKERS; ENDPOINT DETERMINATION; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0642371012     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.16.4.327     Document Type: Review

References (21)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1A-38A.
2. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12.
3. Stevenson LW, Braunwald E. Recognition and management of patients with heart failure. In: Goldman L, Braunwald E, Zorab R, editors. Primary cardiology. Philadelphia: W B Sanders, 1998:310-29.
4. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135(5 Pt 1):825-32.
5. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ 1994;308:1615-9.
6. Cheung BM, Kumana CR. Natriuretic peptides - relevance in cardiac disease. JAMA 1998;280:1983-4.
7. Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding as a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989;159:1427-34.
8. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274(5 Pt 2):H1684-9.
9. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
10. Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol 1986;8:966-70.
11. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
12. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
13. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
14. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
15. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
16. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9.
17. Cheung BM, Kumana CR. Natriuretic peptide - relevance in cardiovascular disease. JAMA 1998;280:1983-4.
18. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
19. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
20. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-3.
21. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.